Equity Overview
Price & Market Data
Price: $2.17
Daily Change: -$0.12 / 5.53%
Daily Range: $2.17 - $2.26
Market Cap: $89,153,872
Daily Volume: 7,418
Performance Metrics
1 Week: -4.41%
1 Month: -8.44%
3 Months: -12.85%
6 Months: 37.34%
1 Year: 57.25%
YTD: 29.17%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.